<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11316">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584831</url>
  </required_header>
  <id_info>
    <org_study_id>CR-0725</org_study_id>
    <secondary_id>J07-416</secondary_id>
    <nct_id>NCT00584831</nct_id>
  </id_info>
  <brief_title>Effect of Eye Movement on Toric Lens Orientation and Visual Acuity</brief_title>
  <official_title>Development and Implementation of a Clinical Test to Investigate the Change in Vision With Soft Toric Contact Lenses During Eye Movements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The relative performance of a new toric soft contact lens against toric contact lenses
      currently available in market, specifically for visual acuity and lens orientation. The
      study will be conducted in a staged approach (2 stages).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-dispensing, single-masked (subject-masked), randomised, controlled study. Two visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual Acuity After Infero-temporal Version Movement.</measure>
    <time_frame>10 minutes after insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity After Infero-nasal Version Movement.</measure>
    <time_frame>10 minutes after lens insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity After Superior-temporal Version Movement</measure>
    <time_frame>10 minutes after lens insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity After Superior-nasal Version Movement.</measure>
    <time_frame>10 minutes after lens insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
  </primary_outcome>
  <number_of_arms>19</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>Group 2 LSBO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: lotrafilcon B toric, senofilcon A toric, balafilcon A toric, omafilcon A toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 LOSB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: lotrafilcon B toric, omafilcon A toric, senofilcon A toric, balafilcon A toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 LBSO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, senofilcon A toric, omafilcon A toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 LBOS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, omafilcon A toric, senofilcon A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6 SLOB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, omafilcon A toric, balafilcon A toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7 SLBO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, balafilcon A toric, omafilcon A toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8 SOLB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: senofilcon A toric, omafilcon A toric, lotrafilcon B toric, balafilcon A toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9 SBLO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: senofilcon A toric, balafilcon A toric, lotrafilcon B toric, omafilcon A toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10 SBOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: senofilcon A toric, balafilcon A toric, omafilcon A toric, lotrafilcon B toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 11 OSLB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: omafilcon A toric, senofilcon A toric, lotrafilcon B toric, balafilcon A toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 12 OSBL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: omafilcon A toric, senofilcon A toric, balafilcon A toric, lotrafilcon B toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 13 OBLS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: omafilcon A toric, balafilcon A toric, lotrafilcon B toric, senofilcon A toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 14 OBSL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: omafilcon A toric, balafilcon A toric, senofilcon A toric, lotrafilcon B toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 15 BLSO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, senofilcon A toric, omafilcon A toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 16 BLOS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, omafilcon A toric, senofilcon A toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 17 BSOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: balafilcon A toric, senofilcon A toric, omafilcon A toric, lotrafilcon B toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 18 BOLS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: balafilcon A toric, omafilcon A toric, lotrafilcon B toric, senofilcon A toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 19 BOSL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: balafilcon A toric, omafilcon A toric, senofilcon A toric, lotrafilcon B toric</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 LSOB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lenses worn in this order: lotrafilcon B toric/senofilcon A toric/omafilconA toric/balafilcon A toric</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>senofilcon A</intervention_name>
    <description>toric contact lens</description>
    <arm_group_label>Group 2 LSBO</arm_group_label>
    <arm_group_label>Group 3 LOSB</arm_group_label>
    <arm_group_label>Group 4 LBSO</arm_group_label>
    <arm_group_label>Group 5 LBOS</arm_group_label>
    <arm_group_label>Group 6 SLOB</arm_group_label>
    <arm_group_label>Group 7 SLBO</arm_group_label>
    <arm_group_label>Group 8 SOLB</arm_group_label>
    <arm_group_label>Group 9 SBLO</arm_group_label>
    <arm_group_label>Group 10 SBOL</arm_group_label>
    <arm_group_label>Group 11 OSLB</arm_group_label>
    <arm_group_label>Group 12 OSBL</arm_group_label>
    <arm_group_label>Group 13 OBLS</arm_group_label>
    <arm_group_label>Group 14 OBSL</arm_group_label>
    <arm_group_label>Group 15 BLSO</arm_group_label>
    <arm_group_label>Group 16 BLOS</arm_group_label>
    <arm_group_label>Group 17 BSOL</arm_group_label>
    <arm_group_label>Group 18 BOLS</arm_group_label>
    <arm_group_label>Group 19 BOSL</arm_group_label>
    <arm_group_label>Group 1 LSOB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>balafilcon A</intervention_name>
    <description>toric contact lens</description>
    <arm_group_label>Group 2 LSBO</arm_group_label>
    <arm_group_label>Group 3 LOSB</arm_group_label>
    <arm_group_label>Group 4 LBSO</arm_group_label>
    <arm_group_label>Group 5 LBOS</arm_group_label>
    <arm_group_label>Group 6 SLOB</arm_group_label>
    <arm_group_label>Group 7 SLBO</arm_group_label>
    <arm_group_label>Group 8 SOLB</arm_group_label>
    <arm_group_label>Group 9 SBLO</arm_group_label>
    <arm_group_label>Group 10 SBOL</arm_group_label>
    <arm_group_label>Group 11 OSLB</arm_group_label>
    <arm_group_label>Group 12 OSBL</arm_group_label>
    <arm_group_label>Group 13 OBLS</arm_group_label>
    <arm_group_label>Group 14 OBSL</arm_group_label>
    <arm_group_label>Group 15 BLSO</arm_group_label>
    <arm_group_label>Group 16 BLOS</arm_group_label>
    <arm_group_label>Group 17 BSOL</arm_group_label>
    <arm_group_label>Group 18 BOLS</arm_group_label>
    <arm_group_label>Group 19 BOSL</arm_group_label>
    <arm_group_label>Group 1 LSOB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>omafilcon A</intervention_name>
    <description>toric contact lens</description>
    <arm_group_label>Group 2 LSBO</arm_group_label>
    <arm_group_label>Group 3 LOSB</arm_group_label>
    <arm_group_label>Group 4 LBSO</arm_group_label>
    <arm_group_label>Group 5 LBOS</arm_group_label>
    <arm_group_label>Group 6 SLOB</arm_group_label>
    <arm_group_label>Group 7 SLBO</arm_group_label>
    <arm_group_label>Group 8 SOLB</arm_group_label>
    <arm_group_label>Group 9 SBLO</arm_group_label>
    <arm_group_label>Group 10 SBOL</arm_group_label>
    <arm_group_label>Group 11 OSLB</arm_group_label>
    <arm_group_label>Group 12 OSBL</arm_group_label>
    <arm_group_label>Group 13 OBLS</arm_group_label>
    <arm_group_label>Group 14 OBSL</arm_group_label>
    <arm_group_label>Group 15 BLSO</arm_group_label>
    <arm_group_label>Group 16 BLOS</arm_group_label>
    <arm_group_label>Group 17 BSOL</arm_group_label>
    <arm_group_label>Group 18 BOLS</arm_group_label>
    <arm_group_label>Group 19 BOSL</arm_group_label>
    <arm_group_label>Group 1 LSOB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>lotrafilcon B</intervention_name>
    <description>toric contact lens</description>
    <arm_group_label>Group 2 LSBO</arm_group_label>
    <arm_group_label>Group 3 LOSB</arm_group_label>
    <arm_group_label>Group 4 LBSO</arm_group_label>
    <arm_group_label>Group 5 LBOS</arm_group_label>
    <arm_group_label>Group 6 SLOB</arm_group_label>
    <arm_group_label>Group 7 SLBO</arm_group_label>
    <arm_group_label>Group 8 SOLB</arm_group_label>
    <arm_group_label>Group 9 SBLO</arm_group_label>
    <arm_group_label>Group 10 SBOL</arm_group_label>
    <arm_group_label>Group 11 OSLB</arm_group_label>
    <arm_group_label>Group 12 OSBL</arm_group_label>
    <arm_group_label>Group 13 OBLS</arm_group_label>
    <arm_group_label>Group 14 OBSL</arm_group_label>
    <arm_group_label>Group 15 BLSO</arm_group_label>
    <arm_group_label>Group 16 BLOS</arm_group_label>
    <arm_group_label>Group 17 BSOL</arm_group_label>
    <arm_group_label>Group 18 BOLS</arm_group_label>
    <arm_group_label>Group 19 BOSL</arm_group_label>
    <arm_group_label>Group 1 LSOB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. They are aged between 18-39 years.

          2. They understand their rights as a research subject and are willing to sign a
             Statement of Informed Consent.

          3. They are willing and able to follow the protocol.

          4. They can attain at least 6/9 in each eye with their spectacle refraction.

          5. They have successfully worn contact lenses within six months of starting the study.

          6. They can be fitted with toric soft contact lenses to match the available power range.

        Exclusion Criteria:

          1. They have an ocular disorder which would normally contra-indicate contact lens wear.

          2. They have a systemic disorder which would normally contra-indicate contact lens wear.

          3. They are using any topical medication such as eye drops or ointment.

          4. They are aphakic.

          5. They have had corneal refractive surgery.

          6. They have any corneal distortion resulting from previous hard or rigid lens wear or
             have keratoconus.

          7. They are pregnant or lactating.

          8. They have grade 2 or greater of any of the following ocular surface signs: corneal
             oedema, corneal vascularisation, corneal staining, tarsal conjunctival changes or any
             other abnormality which would normally contraindicate contact lens wear.

          9. They have taken part in any other clinical trial or research, within two weeks prior
             to starting this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Morgan, PhD MCOptom</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eurolens Research, The University of Manchester Dpt. of Optometry and Neuroscience</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurolens Research, The University of Manchester Dpt. of Optometry &amp; Neuroscience</name>
      <address>
        <city>Manchester</city>
        <zip>M60 1QD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 5, 2015</lastchanged_date>
  <firstreceived_date>December 20, 2007</firstreceived_date>
  <firstreceived_results_date>September 24, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>astigmatism</keyword>
  <keyword>visual acuity</keyword>
  <keyword>orientation</keyword>
  <keyword>contact lenses</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group1 LSOB</title>
          <description>lotrafilcon b toric, senofilcon A toric, omafilcon A toric, balafilcon A toric</description>
        </group>
        <group group_id="P2">
          <title>Group 2 LSBO</title>
          <description>lotrafilcon B toric, senofilcon A toric, balafilcon A toric, omafilcon A toric</description>
        </group>
        <group group_id="P3">
          <title>Group 4 LBSO</title>
          <description>lotrafilcon B toric, balafilcon A toric, senofilcon A toric, omafilcon A toric</description>
        </group>
        <group group_id="P4">
          <title>Group 5 LBOS</title>
          <description>lotrafilcon B toric, balafilcon A toric, omafilcon A toric, senofilcon A</description>
        </group>
        <group group_id="P5">
          <title>Group 7 SLBO</title>
          <description>senofilcon A toric, lotrafilcon B toric, balafilcon A toric, omafilcon A toric</description>
        </group>
        <group group_id="P6">
          <title>Group 8 SOLB</title>
          <description>senofilcon A toric, omafilcon A toric, lotrafilcon B toric, balafilcon A toric</description>
        </group>
        <group group_id="P7">
          <title>Group 9 SBLO</title>
          <description>senofilcon A toric, balafilcon A toric, lotrafilcon B toric, omafilcon A toric</description>
        </group>
        <group group_id="P8">
          <title>Group 10 SBOL</title>
          <description>senofilcon A toric, balafilcon A toric, omafilcon A toric, lotrafilcon B toric</description>
        </group>
        <group group_id="P9">
          <title>Group 11 OSLB</title>
          <description>omafilcon A toric, senofilcon A toric, lotrafilcon B toric, balafilcon A toric</description>
        </group>
        <group group_id="P10">
          <title>Group 12 OSBL</title>
          <description>omafilcon A toric, senofilcon A toric, balafilcon A toric, lotrafilcon B toric</description>
        </group>
        <group group_id="P11">
          <title>Group 13 OBLS</title>
          <description>omafilcon A toric, balafilcon A toric, lotrafilcon B toric, senofilcon A toric</description>
        </group>
        <group group_id="P12">
          <title>Group 14 OBSL</title>
          <description>omafilcon A toric, balafilcon A toric, senofilcon A toric, lotrafilcon B toric</description>
        </group>
        <group group_id="P13">
          <title>Group 15 BLSO</title>
          <description>balafilcon A toric, lotrafilcon B toric, senofilcon A toric, omafilcon A toric</description>
        </group>
        <group group_id="P14">
          <title>Group 16 BLOS</title>
          <description>balafilcon A toric, lotrafilcon B toric, omafilcon A toric, senofilcon A toric</description>
        </group>
        <group group_id="P15">
          <title>Group 18 BOLS</title>
          <description>balafilcon A toric, omafilcon A toric, lotrafilcon B toric, senofilcon A toric</description>
        </group>
        <group group_id="P16">
          <title>Group 19 BOSL</title>
          <description>balafilcon A toric, omafilcon A toric, senofilcon A toric, lotrafilcon B toric</description>
        </group>
        <group group_id="P17">
          <title>Group 3 LOSB</title>
          <description>lotrafilcon B toric, omafilcon A toric, senofilcon A toric, balafilcon A toric</description>
        </group>
        <group group_id="P18">
          <title>Group 6 SLOB</title>
          <description>senofilcon A toric, lotrafilcon b toric, omafilcon A toric, balafilcon A toric</description>
        </group>
        <group group_id="P19">
          <title>Group 17 BSOL</title>
          <description>balafilcon A toric, senofilcon A toric,omafilcon A toric, lotrafilcon b toric</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="4"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="4"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="4"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="4"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="4"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="4"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="4"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="4"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Study Population</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="28.3" spread="7.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity After Infero-temporal Version Movement.</title>
        <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
        <time_frame>10 minutes after insertion</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Lotrafilcon B</title>
            <description>lotrafilcon b toric</description>
          </group>
          <group group_id="O2">
            <title>Senofilcon A</title>
            <description>senofilcon A toric</description>
          </group>
          <group group_id="O3">
            <title>Omafilcon A</title>
            <description>omafilcon A toric</description>
          </group>
          <group group_id="O4">
            <title>Balafilcon A</title>
            <description>balafilcon A toric</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="35"/>
                  <measurement group_id="O4" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Visual Acuity After Infero-temporal Version Movement.</title>
            <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
            <units>LogMAR units</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.12" spread="0.16"/>
                  <measurement group_id="O2" value="0.1" spread="0.15"/>
                  <measurement group_id="O3" value="0.16" spread="0.17"/>
                  <measurement group_id="O4" value="0.14" spread="0.19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hyposthesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity After Infero-nasal Version Movement.</title>
        <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
        <time_frame>10 minutes after lens insertion</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Lotrafilcon B</title>
            <description>lotrafilcon b toric</description>
          </group>
          <group group_id="O2">
            <title>Senofilcon A</title>
            <description>senofilcon A toric</description>
          </group>
          <group group_id="O3">
            <title>Omafilcon A</title>
            <description>omafilcon A toric</description>
          </group>
          <group group_id="O4">
            <title>Balafilcon A</title>
            <description>balafilcon A toric</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="35"/>
                  <measurement group_id="O4" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Visual Acuity After Infero-nasal Version Movement.</title>
            <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
            <units>LogMAR units</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.12" spread="0.16"/>
                  <measurement group_id="O2" value="0.11" spread="0.16"/>
                  <measurement group_id="O3" value="0.14" spread="0.17"/>
                  <measurement group_id="O4" value="0.15" spread="0.20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.03</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.03</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity After Superior-temporal Version Movement</title>
        <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
        <time_frame>10 minutes after lens insertion</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Lotrafilcon B</title>
            <description>lotrafilcon b toric</description>
          </group>
          <group group_id="O2">
            <title>Senofilcon A</title>
            <description>senofilcon A toric</description>
          </group>
          <group group_id="O3">
            <title>Omafilcon A</title>
            <description>omafilcon A toric</description>
          </group>
          <group group_id="O4">
            <title>Balafilcon A</title>
            <description>balafilcon A toric</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="35"/>
                  <measurement group_id="O4" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Visual Acuity After Superior-temporal Version Movement</title>
            <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
            <units>LogMAR units</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.11" spread="0.15"/>
                  <measurement group_id="O2" value="0.08" spread="0.14"/>
                  <measurement group_id="O3" value="0.13" spread="0.17"/>
                  <measurement group_id="O4" value="0.14" spread="0.20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity After Superior-nasal Version Movement.</title>
        <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
        <time_frame>10 minutes after lens insertion</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Lotrafilcon B</title>
            <description>lotrafilcon b toric</description>
          </group>
          <group group_id="O2">
            <title>Senofilcon A</title>
            <description>senofilcon A toric</description>
          </group>
          <group group_id="O3">
            <title>Omafilcon A</title>
            <description>omafilcon A toric</description>
          </group>
          <group group_id="O4">
            <title>Balafilcon A</title>
            <description>balafilcon A toric</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="35"/>
                  <measurement group_id="O4" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Visual Acuity After Superior-nasal Version Movement.</title>
            <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
            <units>LogMAR units</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.14" spread="0.15"/>
                  <measurement group_id="O2" value="0.10" spread="0.15"/>
                  <measurement group_id="O3" value="0.15" spread="0.16"/>
                  <measurement group_id="O4" value="0.16" spread="0.19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.05</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that visual acuity is the same for all lens types.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The non-inferiority margin is 0.05</non_inferiority_desc>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lotrafilcon B</title>
          <description>lotrafilcon b toric contact lens</description>
        </group>
        <group group_id="E2">
          <title>Senofilcon A</title>
          <description>senofilcon A toric contact lens</description>
        </group>
        <group group_id="E3">
          <title>Omafilcon A</title>
          <description>omafilcon A toric contact lens</description>
        </group>
        <group group_id="E4">
          <title>Balafilcon A</title>
          <description>balafilcon A toric contact lens</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kurt Moody, OD, FAAO</name_or_title>
      <organization>Vistakon</organization>
      <phone>904-443-3088</phone>
      <email>kmoody1@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
